AMD | Ophthalmology Innovation Source

Iconic Therapeutics

Participant: William L. Greene, MD Dr. Greene has served as CEO of Iconic Therapeutics since 2014. He brings 20 years of experience as an operating executive, clinician, investor, and entrepreneur. View Full Profile

PanOptica

Participant: Paul Chaney Paul G. Chaney is Co-Founder, President & CEO of PanOptica Inc., a biopharma company developing PAN-90806, a novel topical anti-VEGF treatment for neovascular eye diseases. View Full Profile

Ophthotech Corporation

Fovista is an anti-platelet derived growth factor (PDGF) agent for wet age-related macular degeneration (AMD) combination therapy currently in phase 3 studies. Pending regulatory approval, Ophthotech will commercialize Fovista in the U.S., and has partnered with Novartis outside the U.S. in a deal worth more than $1 billion in upfront and potential milestone payments. The…

Second Sight Medical Products

The Argus II transmits images wirelessly to a layer of 60 tiny electrodes on the retina inside the eye, to reverse vision lost as a result of retinitis pigmentosa (RP). The product is commercial stage, approved in the United States, Canada, European Union, Turkey, and elsewhere. RP is a hereditary disease; the Argus II is…

RetroSense Therapeutics

[c RetroSense Therapeutics CEO Sean Ainsworth explains how the company’s optogenetic gene therapeutic can impart light sensitivity to cells in the retina, re-sensitizing it to light. The company is pursuing treatments for Dry AMD and retinitis pigementosa. RetroSense Therapeutics is developing optogenetic gene therapeutic approaches to vision restoration. Optogenetics imparts light sensitivity to cells in…

Graybug

Graybug is developing injectable controlled-release technologies to allow dosing once every four to six months for the treatment of neovascular age-related macular degeneration (AMD), thereby reducing patient burden from 20+ injections yearly to two to three injections. The company is planning to file an Investigational New Drug application before year-end. Graybug licensed the simple, particle…

OcuSciences Hopes To Give Early Warning On Ocular Disease

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 057″] Kurt Riegger, President and COO of OcuSciences, tells a start-up’s tale. OcuSciences’ OcuMet Beacon is being developed to give optometrists and ophthalmologies the ability to see the onset of disease earlier than ever. Transcript: Tom Salemi: Hi, everyone. This is Tom Salemi, content director of Healthegy and your host of…

Opthea Exploring Different Approach To Treating Wet AMD

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 055″] Australia-based Opthea is moving forward with clinical trials in the US, testing its OPT-302 compound along and in combination with Lucentis as a potential treatment for Wet AMD. CEO Megan Baldwin explains the company’s approach up until now and its plans going forward. Podcast Guest Megan Baldwin Dr. Megan Baldwin…

First Lucentis Biosimilar Launches in India, but Path in US not so Clear

The first biosimilar agent for Lucentis (ranibizumab, Genentech) has come to market in India with the launch of Intas Pharmaceuticals’’ Razumab in June. But whether biosimilar agents gain any traction in the United States remains to be seen as they must overcome myriad regulatory and competitive hurdles. Biosimilars are to branded biologic agents like Lucentis…

Investors Move Fast on AERI, AAVL Clinical News

Two presenters at the OIS saw their stock prices shoot in different directions following the release of news related to late-stage clinical trials. On Tuesday, Aerie Pharmaceuticals, received approval from the Food and Drug Administration to change the primary endpoint of its second Phase 3 trial of Rhopressa, its rho kinase (ROCK) inhibitor for reduction…

Second Sight Fulfills Dream

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 022″] Second Sight President & CEO Robert Greenberg, MD, PhD looks back on Second Sight’s long road to getting FDA approval for Argus II and considers the path not taken. Podcast Guest Robert Greenberg, MD, PhD Dr. Greenberg currently serves as Chairman of the Board of Second Sight Medical Products. He…

Biopharma Companies of All Stages Shine in OIS Showcase

Biopharmaceutical development has gone well beyond the drugs themselves to mechanisms and platforms that aim to deliver those drugs more effectively and precisely than existing platforms, as nearly 800 attendees at the Ophthalmology Innovation Summit in Chicago heard during the BioPharma Showcase. Read the key takeaways below on the companies that presented, and watch the…